Takeda is a global, values-based, digital biopharmaceutical company committed to developing and delivering life-transforming treatment options to patients globally.

In China, we have seen significant progress toward accelerating access to these treatments. I'm confident in China's commitment to improving the health of its population and believe that this is a critical part of the country's successful modernization efforts. Better health for people is Takeda's purpose and we're very pleased that three Takeda medicines – two in oncology, one in rare disease – were added to the 2022 National Reimbursement Drug List.

In fact, we're on track to launch more than 15 innovative medicines by 2025. We look forward to continuing our work in China to ensure that patients who need our medicines have access to them.